Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Read More

Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

Read More

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

Read More

Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

Read More

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

Read More

Ryvu Therapeutics presents its Development Plans for 2022-2024, aims to accelerate its mission

Read More

EIB to support Ryvu Therapeutics’ discovery, research and development of new cancer treatments with €22 million

Read More

Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board

Read More

Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies

Read More

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Read More